Cozaar (Losartan D4) first listed in 1994 , is now in 93 countries have been approved for use for the treatment of hypertension . Hyzaar including the United States have been in 74 countries have been approved for use .
Merck currently apply in some countries outside the United States Cozaar treatment of heart failure indications. And have been registered in 12 countries for the treatment of those who are no longer suitable for the application of angiotensin -converting enzyme inhibitor (ACEI) therapy.
Cozaar and Hyzaar are AIIA class of drugs most prescribed drugs in the world, sales of anti-hypertensive drugs qualifying third . Since the advent of the drug , there have been more than 10 million patients who have taken Cozaar and Hyzaar . As these drugs Cozaar most widely studied drugs , there are more than 4,000 scientific papers published . Cozaar and Hyzaar are developed by Merck .
In order to assess the therapeutic effect of Cozaar , especially in improving hypertension, heart failure and recent heart attack survival rates , reduce morbidity , it has already launched a series of large-scale endpoint studies, including LIFE ( Cozaar treatment of hypertension survival Study ) and OPTIMAAL ( Cozaar after myocardial infarction study ) .
For Cozaar Kidney Protection Study (RENAAL) has published the annual meeting of American Society of Hypertension . This new landmark study achieved its primary goal , the first time demonstrated Cozaar for hypertension associated with type 2 diabetic nephropathy patients with renal protection . Cozaar group in patients with end-stage renal disease risk reduction of 28 %, usually these patients require dialysis and kidney transplant to maintain life .
Advances in clinical medicine
Calcium channel blockers and losartan in patients with hypertension can reduce the risk of gout (BMJ. 2012 Jan 12; 344: d8190. Doi: 10.1136/bmj.d8190.)
Topic : Different types of antihypertensive drugs on the incidence of gout : a population-based case-control study (Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study.)
Objective: This study was designed to study the application of antihypertensive drugs in patients with hypertension and the risk of gout independent association between .
Design: nested case- control study .
Setting : UK General Practice Research Database Health 2000-2007 .
Study subjects: 24,768 cases aged 20-79 years adult patients with gout , 50,000 cases of the control group were randomly paired samples .
Key indicators: antihypertensive drugs associated with the application of the relative risk of gout onset .
Results: The age, gender, body mass index , medical status, alcohol and drugs and related complications after adjustment for patients with hypertension (N = 29138) antihypertensive drug-related causes gout multivariate relative risks were: calcium channel antagonists 0.87 ( 95% confidence interval 0.82 to 0.93 ) , losartan 0.81 ( 0.70 to 0.94 ) , diuretics 2.36 (2.21至2.52), β receptor antagonists 1.48 ( 1.40 to 1.57 ) , angiotensin-converting inhibitors 1.24 ( 1.17 to 1.32 ) , non- angiotensin Ⅱ receptor antagonist losartan 1.29 ( 1.16 to 1.43 ) . Non-hypertensive patients studied yielded similar results. Hypertensive patients with calcium channel antagonists length of time multivariate relative risks were: <1 year 1.02,1-1.9 years 0.88, ≥ 2 years was 0.75 , while losartan were 0.98,0.87 and 0.71 (P for trend <0.05 ) .
CONCLUSIONS: Consistent with decreased uric acid , calcium channel antagonists and losartan in patients with hypertension can reduce the risk of gout . In contrast , diuretics , β receptor antagonists, angiotensin converting enzyme inhibitors and non- losartan angiotensin Ⅱ receptor antagonist associated with increased risk of gout .
More about:Losartan D4 manufacturer
From:Natural herbal extracts
No comments:
Post a Comment